Gilead Sciences (GILD) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	0-19731
Entity Registrant Name	GILEAD SCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3047598
Entity Address, Address Line One	333 Lakeside Drive
Entity Address, City or Town	Foster City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94404
City Area Code	650
Local Phone Number	574-3000
Title of each class	Common Stock, par value, $0.001 per share
Trading Symbol(s)	GILD
Name of each exchange on which registered	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,246,265,857
Entity Central Index Key	0000882095
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 5,037	$ 6,085
Short-term marketable debt securities	0	1,179
Accounts receivable, net	4,587	4,660
Inventories	1,869	1,787
Prepaid and other current assets	3,287	2,374
Total current assets	14,779	16,085
Property, plant and equipment, net	5,391	5,317
Long-term marketable debt securities	0	1,163
Intangible assets, net	20,546	26,454
Goodwill	8,314	8,314
Other long-term assets	5,494	4,792
Total assets	54,525	62,125
Current liabilities:
Accounts payable	903	550
Accrued rebates	4,113	3,802
Current portion of long-term debt and other obligations, net	1,812	1,798
Other current liabilities	4,896	5,130
Total current liabilities	11,725	11,280
Long-term debt, net	21,437	23,189
Long-term income taxes payable	782	2,039
Deferred tax liability	794	1,588
Other long-term obligations	1,396	1,280
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding	0	0
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,246 shares issued and outstanding	1	1
Additional paid-in capital	7,327	6,500
Accumulated other comprehensive income	73	28
Retained earnings	11,073	16,304
Total Gilead stockholders’ equity	18,475	22,833
Noncontrolling interest	(84)	(84)
Total stockholders’ equity	18,390	22,749
Total liabilities and stockholders’ equity	$ 54,525	$ 62,125

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2024	Dec. 31, 2023
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	5	5
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	5,600	5,600
Common stock, issued (in shares)	1,246	1,246
Common stock, outstanding (in shares)	1,246	1,246

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 7,545	$ 7,051	$ 21,185	$ 20,002
Costs and expenses:
Cost of goods sold	1,574	1,565	4,670	4,408
Research and development expenses	1,395	1,457	4,266	4,310
Acquired in-process research and development expenses	505	91	4,674	808
In-process research and development impairment	1,750	0	4,180	0
Selling, general and administrative expenses	1,433	1,315	4,184	4,482
Total costs and expenses	6,657	4,428	21,975	14,009
Operating income (loss)	888	2,623	(790)	5,993
Interest expense	238	232	728	692
Other (income) expense, net	(306)	72	(41)	95
Income (loss) before income taxes	956	2,318	(1,477)	5,206
Income tax (benefit) expense	(297)	146	(174)	1,010
Net income (loss)	1,253	2,172	(1,303)	4,196
Net loss attributable to noncontrolling interest	0	(8)	0	(40)
Net income (loss) attributable to Gilead	$ 1,253	$ 2,180	$ (1,303)	$ 4,236
Basic earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1	$ 1.75	$ (1.04)	$ 3.39
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares)	1,247	1,248	1,247	1,249
Diluted earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1	$ 1.73	$ (1.04)	$ 3.37
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares)	1,254	1,257	1,247	1,259
Product sales
Revenues:
Total revenues	$ 7,515	$ 6,994	$ 21,074	$ 19,864
Royalty, contract and other revenues
Revenues:
Total revenues	$ 30	$ 56	$ 111	$ 138

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 1,253	$ 2,172	$ (1,303)	$ 4,196
Other comprehensive (loss) income, net:
Net foreign currency translation gain (loss)	54	(35)	38	(3)
Available-for-sale debt securities:
Net unrealized gain, net of tax impact of $0, $0, $0 and $0, respectively	0	4	0	10
Reclassifications to net income (loss), net of tax impact of $0, $0, $0 and $0, respectively	0	0	5	2
Net change	0	5	5	11
Cash flow hedges:
Net unrealized (loss) gain, net of tax impact of $(9), $9, $3 and $9, respectively	(61)	66	20	65
Reclassifications to net income (loss), net of tax impact of $2, $2, $2 and $6, respectively	(12)	(14)	(17)	(44)
Net change	(74)	51	3	21
Other comprehensive (loss) income, net	(20)	21	45	30
Comprehensive income (loss), net	1,233	2,193	(1,258)	4,226
Comprehensive loss attributable to noncontrolling interest, net	0	(8)	0	(40)
Comprehensive income (loss) attributable to Gilead, net	$ 1,233	$ 2,201	$ (1,258)	$ 4,265

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Available-for-sale debt securities:
Tax impact of net unrealized gain	$ 0	$ 0	$ 0	$ 0
Tax impact of reclassifications to net income (loss)	0	0	0	0
Cash flow hedges:
Tax impact of net unrealized (loss) gain	(9)	9	3	9
Tax impact of reclassifications to net income (loss)	$ 2	$ 2	$ 2	$ 6

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Retained Earnings	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2022		1,247
Beginning balance at Dec. 31, 2022	$ 21,209	$ 1	$ 5,550	$ 2	$ 15,687	$ (31)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	4,196				4,236	(40)
Other comprehensive income (loss), net	30			30
Issuances under employee stock purchase plan (in shares)		2
Issuances under employee stock purchase plan	129		129
Issuance under equity incentive plans (in shares)		11
Issuances under equity incentive plans	71		71
Stock-based compensation	566		566
Repurchases of common stock under repurchase programs (in shares)		(11)
Repurchases of common stock under repurchase programs	(850)		(38)		(812)
Repurchases of common stock for employee tax withholding under equity incentive plans (in shares)		(3)
Repurchases of common stock for employee tax withholding under equity incentive plans	(245)				(245)
Dividends declared	(2,864)				(2,864)
Ending balance (in shares) at Sep. 30, 2023		1,247
Ending balance at Sep. 30, 2023	22,242	$ 1	6,279	31	16,002	(72)
Beginning balance (in shares) at Jun. 30, 2023		1,247
Beginning balance at Jun. 30, 2023	21,094	$ 1	6,008	10	15,138	(64)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	2,172				2,180	(8)
Other comprehensive income (loss), net	21			21
Issuances under employee stock purchase plan (in shares)		1
Issuances under employee stock purchase plan	62		62
Issuance under equity incentive plans (in shares)		4
Issuances under equity incentive plans	21		21
Stock-based compensation	202		202
Repurchases of common stock under repurchase programs (in shares)		(4)
Repurchases of common stock under repurchase programs	(300)		(14)		(286)
Repurchases of common stock for employee tax withholding under equity incentive plans and other (in shares)		(1)
Repurchases of common stock for employee tax withholding under equity incentive plans and other	(77)				(77)
Dividends declared	(953)				(953)
Ending balance (in shares) at Sep. 30, 2023		1,247
Ending balance at Sep. 30, 2023	$ 22,242	$ 1	6,279	31	16,002	(72)
Beginning balance (in shares) at Dec. 31, 2023	1,246	1,246
Beginning balance at Dec. 31, 2023	$ 22,749	$ 1	6,500	28	16,304	(84)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(1,303)				(1,303)
Other comprehensive income (loss), net	45			45
Issuances under employee stock purchase plan (in shares)		2
Issuances under employee stock purchase plan	139		139
Issuance under equity incentive plans (in shares)		12
Issuances under equity incentive plans	115		115
Stock-based compensation	613		613
Repurchases of common stock under repurchase programs (in shares)		(11)
Repurchases of common stock under repurchase programs	(800)		(40)		(760)
Repurchases of common stock for employee tax withholding under equity incentive plans and other (in shares)		(3)
Repurchases of common stock for employee tax withholding under equity incentive plans and other	(232)				(232)
Dividends declared	$ (2,935)				(2,935)
Ending balance (in shares) at Sep. 30, 2024	1,246	1,246
Ending balance at Sep. 30, 2024	$ 18,390	$ 1	7,327	73	11,073	(84)
Beginning balance (in shares) at Jun. 30, 2024		1,246
Beginning balance at Jun. 30, 2024	18,197	$ 1	7,022	93	11,165	(84)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	1,253				1,253
Other comprehensive income (loss), net	(20)			(20)
Issuances under employee stock purchase plan (in shares)		1
Issuances under employee stock purchase plan	58		58
Issuance under equity incentive plans (in shares)		4
Issuances under equity incentive plans	45		45
Stock-based compensation	216		216
Repurchases of common stock under repurchase programs (in shares)		(4)
Repurchases of common stock under repurchase programs	(300)		(15)		(285)
Repurchases of common stock for employee tax withholding under equity incentive plans and other (in shares)		(1)
Repurchases of common stock for employee tax withholding under equity incentive plans and other	(82)				(82)
Dividends declared	$ (977)				(977)
Ending balance (in shares) at Sep. 30, 2024	1,246	1,246
Ending balance at Sep. 30, 2024	$ 18,390	$ 1	$ 7,327	$ 73	$ 11,073	$ (84)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Average price per share (in dollars per share)	$ 76.30	$ 77.08	$ 75.23	$ 79.92
Common stock, dividends declared (in dollars per share)	$ 0.77	$ 0.75	$ 2.31	$ 2.25

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating Activities:
Net (loss) income	$ (1,303)	$ 4,196
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation expense	286	263
Amortization expense	1,788	1,742
Stock-based compensation expense	613	565
Deferred income taxes	(1,465)	(592)
Net loss from equity securities	148	356
Acquired in-process research and development expenses	4,674	808
In-process research and development impairment	4,180	0
Other	294	260
Changes in operating assets and liabilities:
Accounts receivable, net	67	(63)
Inventories	(200)	(535)
Prepaid expenses and other	(113)	71
Accounts payable	348	(304)
Income tax assets and liabilities, net	(1,268)	(1,070)
Accrued and other liabilities	(197)	141
Net cash provided by operating activities	7,853	5,837
Investing Activities:
Purchases of marketable debt securities	(244)	(1,474)
Proceeds from sales of marketable debt securities	2,265	412
Proceeds from maturities of marketable debt securities	327	985
Acquisitions, including in-process research and development, net of cash acquired	(4,765)	(873)
Purchases of equity securities	(453)	(218)
Capital expenditures	(376)	(370)
Other	23	0
Net cash used in investing activities	(3,224)	(1,538)
Financing Activities:
Proceeds from debt financing, net of issuance costs	0	1,979
Proceeds from issuances of common stock	249	206
Repurchases of common stock under repurchase programs	(800)	(850)
Repayments of debt and other obligations	(1,963)	(2,250)
Payments of dividends	(2,945)	(2,866)
Other	(234)	(245)
Net cash used in financing activities	(5,693)	(4,026)
Effect of exchange rate changes on cash and cash equivalents	15	20
Net change in cash and cash equivalents	(1,049)	293
Cash and cash equivalents at beginning of period	6,085	5,412
Cash and cash equivalents at end of period	$ 5,037	$ 5,705

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (“Gilead,” “we,” “our” or “us”) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2023, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2024, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03 “Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” ASU 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 annual report to be filed in early 2028 and all quarterly and annual reports thereafter. We expect the adoption of this standard to result in increased disclosures in our Notes to Consolidated Financial Statements.

REVENUES

REVENUES	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
REVENUES	REVENUES Disaggregation of Revenues The following table summarizes our Total revenues: Three Months Ended September 30, 2024 Three Months Ended September 30, 2023 (in millions) U.S. Europe Rest of World Total U.S. Europe Rest of World Total Product sales: HIV Biktarvy $ 2,826 $ 375 $ 272 $ 3,472 $ 2,504 $ 313 $ 268 $ 3,085 Descovy 534 24 28 586 460 25 26 511 Genvoya 384 44 21 449 433 47 23 503 Odefsey 248 69 9 326 257 74 11 343 Symtuza - Revenue share (1) 103 33 3 139 96 32 3 131 Other HIV (2) 65 26 9 100 56 28 9 94 Total HIV 4,161 570 342 5,073 3,807 519 341 4,667 Liver Disease Sofosbuvir/Velpatasvir (3) 222 67 96 385 215 76 85 377 Vemlidy 126 11 95 232 112 9 106 228 Other Liver Disease (4) 45 54 17 116 49 33 20 102 Total Liver Disease 393 132 207 733 376 119 211 706 Veklury 393 81 219 692 258 65 313 636 Oncology Cell Therapy Tecartus 63 29 6 98 64 27 4 96 Yescarta 145 182 60 387 197 154 40 391 Total Cell Therapy 208 211 66 485 261 181 45 486 Trodelvy 226 80 26 332 201 62 21 283 Total Oncology 433 291 92 816 462 243 65 769 Other AmBisome 6 71 52 130 12 63 39 115 Other (5) 47 8 16 71 69 9 23 101 Total Other 53 80 68 201 82 72 62 216 Total product sales 5,433 1,154 928 7,515 4,985 1,017 992 6,994 Royalty, contract and other revenues 17 13 1 30 32 23 1 56 Total revenues $ 5,450 $ 1,167 $ 929 $ 7,545 $ 5,017 $ 1,040 $ 993 $ 7,051 Nine Months Ended September 30, 2024 Nine Months Ended September 30, 2023 (in millions) U.S. Europe Rest of World Total U.S. Europe Rest of World Total Product sales: HIV Biktarvy $ 7,726 $ 1,110 $ 814 $ 9,649 $ 7,104 $ 920 $ 717 $ 8,741 Descovy 1,339 75 82 1,496 1,314 75 86 1,475 Genvoya 1,088 138 66 1,292 1,305 157 81 1,544 Odefsey 705 217 30 952 754 223 33 1,011 Symtuza - Revenue share (1) 338 101 9 448 278 101 10 390 Other HIV (2) 190 96 36 322 192 91 38 321 Total HIV 11,386 1,737 1,038 14,160 10,949 1,568 965 13,482 Liver Disease Sofosbuvir/Velpatasvir (3) 737 230 299 1,266 643 250 266 1,159 Vemlidy 338 33 328 699 295 28 322 645 Other Liver Disease (4) 134 148 55 337 113 112 64 289 Total Liver Disease 1,210 411 682 2,302 1,051 390 652 2,093 Veklury 784 204 473 1,461 607 227 630 1,465 Oncology Cell Therapy Tecartus 181 102 22 305 179 83 11 272 Yescarta 502 509 170 1,181 624 408 99 1,130 Total Cell Therapy 683 611 192 1,485 802 491 109 1,402 Trodelvy 655 217 88 960 551 169 44 764 Total Oncology 1,338 828 280 2,446 1,354 660 153 2,167 Other AmBisome 37 210 176 424 39 192 150 381 Other (5) 203 26 52 281 197 31 49 277 Total Other 241 236 228 705 236 224 199 658 Total product sales 14,958 3,416 2,700 21,074 14,196 3,069 2,599 19,864 Royalty, contract and other revenues 66 43 2 111 57 77 4 138 Total revenues $ 15,024 $ 3,459 $ 2,703 $ 21,185 $ 14,253 $ 3,146 $ 2,603 $ 20,002 _______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). (2) Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig. Revenues Recognized from Performance Obligations Satisfied in Prior Years The following table summarizes revenues recognized from performance obligations satisfied in prior years: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Revenue share with Janssen and royalties for licenses of intellectual property $ 173 $ 166 $ 545 $ 517 Changes in estimates $ 146 $ 111 $ 388 $ 347 Contract Balances The following table summarizes our contract balances: (in millions) September 30, 2024 December 31, 2023 Contract assets $ 184 $ 117 Contract liabilities $ 68 $ 109

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: September 30, 2024 December 31, 2023 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Available-for-sale debt securities (1) : U.S. treasury securities $ — $ — $ — $ — $ 426 $ — $ — $ 426 U.S. government agencies securities — — — — — 127 — 127 Non-U.S. government securities — — — — — 10 — 10 Certificates of deposit — — — — — 45 — 45 Corporate debt securities — — — — — 1,451 — 1,451 Residential mortgage and asset-backed securities — — — — — 367 — 367 Equity securities: Money market funds 3,502 — — 3,502 4,465 — — 4,465 Publicly traded equity securities (2) 1,665 — — 1,665 1,458 — — 1,458 Deferred compensation plan 343 — — 343 284 — — 284 Foreign currency derivative contracts — 7 — 7 — 7 — 7 Total $ 5,510 $ 7 $ — $ 5,517 $ 6,633 $ 2,007 $ — $ 8,639 Liabilities: Liability for MYR GmbH (“MYR”) contingent consideration $ — $ — $ 222 $ 222 $ — $ — $ 228 $ 228 Deferred compensation plan 343 — — 343 283 — — 283 Foreign currency derivative contracts — 49 — 49 — 59 — 59 Total $ 343 $ 49 $ 222 $ 615 $ 283 $ 59 $ 228 $ 570 _______________________________ (1) During the three months ended March 31, 2024, we sold all of our available-for-sale debt securities and used the proceeds to partially fund our acquisition of CymaBay Therapeutics, Inc. (“CymaBay”) discussed in Note 6. Acquisitions, Collaborations and Other Arrangements. (2) Publicly traded equity securities include our investment in Arcellx, Inc. (“Arcellx”) of $561 million as of September 30, 2024, which is subject to contractual sale restrictions until June 2025. Level 2 Inputs Available-for-Sale Debt Securities For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. Foreign Currency Derivative Contracts Our foreign currency derivative contracts have maturities of 18 months or less and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P Global Ratings, Moody’s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by utilizing an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (“SOFR”) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals. Senior Unsecured Notes The following table summarizes the total estimated fair value and carrying value of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values: (in millions) September 30, 2024 December 31, 2023 Fair value $ 20,931 $ 22,567 Carrying value $ 22,094 $ 23,834 Level 3 Inputs Contingent Consideration Liability In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to €300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (“FDA”) approval of Hepcludex until the related contingency is resolved. The following table summarizes the change in fair value of our contingent consideration liability: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Beginning balance $ 208 $ 288 $ 228 $ 275 Changes in valuation assumptions (1) 5 (2) (6) 3 Effect of foreign exchange remeasurement (2) 9 (11) 1 (4) Ending balance (3) $ 222 $ 275 $ 222 $ 275 ________________________________ (1) Included in Research and development expenses on our Condensed Consolidated Statements of Operations. The changes in 2024 and 2023 primarily related to changes in discount rates and assumptions around probability and timing of regulatory approval. (2) Included in Other (income) expense, net on our Condensed Consolidated Statements of Operations. (3) Included in Other long-term obligations on our Condensed Consolidated Balance Sheets. Liability Related to Future Royalties We recorded a liability related to future royalties as part of our 2020 acquisition of Immunomedics, Inc. (“Immunomedics”), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair value of the liability related to future royalties was approximately $1.0 billion and $1.2 billion as of September 30, 2024 and December 31, 2023, respectively, and the carrying value was $1.2 billion as of September 30, 2024 and December 31, 2023. Nonrecurring Fair Value Measurements During the three and nine months ended September 30, 2024, we recorded partial impairment charges of $1.8 billion and $4.2 billion , respectively, related to certain acquired in-process research and development (“IPR&D”) assets. See Note 7. Intangible Assets for additional information. Fair Value Level Transfers There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.

AVAILABLE-FOR-SALE DEBT SECURIT

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES	9 Months Ended
	Sep. 30, 2024
Debt Securities, Available-for-Sale [Abstract]
AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES	AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES Available-for-Sale Debt Securities During the three months ended March 31, 2024, we sold all of our available-for-sale debt securities and used the proceeds to partially fund our acquisition of CymaBay discussed in Note 6. Acquisitions, Collaborations and Other Arrangements. As such, there are no balances as of September 30, 2024 in the following tables. The following table summarizes our available-for-sale debt securities as of December 31, 2023: December 31, 2023 (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 427 $ — $ (1) $ 426 U.S. government agencies securities 127 — — 127 Non-U.S. government securities 10 — — 10 Certificates of deposit 45 — — 45 Corporate debt securities 1,455 4 (8) 1,451 Residential mortgage and asset-backed securities 366 1 — 367 Total $ 2,430 $ 5 $ (10) $ 2,426 The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time, as of December 31, 2023: December 31, 2023 Less Than 12 Months 12 Months or Longer Total (in millions) Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ — $ 161 $ (1) $ 48 $ (1) $ 209 U.S. government agencies securities — 106 — 2 — 108 Non-U.S. government securities — 5 — 5 — 10 Corporate debt securities (1) 333 (7) 546 (8) 878 Residential mortgage and asset-backed securities — 123 — 24 — 147 Total $ (2) $ 727 $ (8) $ 624 $ (10) $ 1,351 The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets as of December 31, 2023: (in millions) December 31, 2023 Cash and cash equivalents $ 83 Short-term marketable debt securities 1,179 Long-term marketable debt securities 1,163 Total $ 2,426 Equity Securities The following table summarizes the classification of our equity securities on our Condensed Consolidated Balance Sheets: (in millions) September 30, 2024 December 31, 2023 Equity securities measured at fair value: Cash and cash equivalents $ 3,502 $ 4,465 Prepaid and other current assets 1,660 1,086 Other long-term assets 348 656 Equity method investments and other equity investments without readily determinable fair values: Other long-term assets 382 $ 340 Total $ 5,892 $ 6,547 For our equity method investments in Galapagos NV (“Galapagos”) and Arcus Biosciences, Inc. (“Arcus”), we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos was classified in Prepaid and other current assets as of September 30, 2024 and December 31, 2023 at $483 million and $686 million, respectively. Our investment in Arcus was classified in Prepaid and other current assets as of September 30, 2024 and December 31, 2023 at $460 million and $283 million, respectively. Unrealized Gains and Losses The following table summarizes net unrealized gains and losses on equity securities still held as of the respective balance sheet dates, included in Other (income) expense, net on our Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Unrealized (gain) loss, net $ (257) $ 128 $ 155 $ 249

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	DERIVATIVE FINANCIAL INSTRUMENTS Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. We held foreign currency exchange contracts with outstanding notional amounts of $2.3 billion and $2.5 billion as of September 30, 2024 and December 31, 2023, respectively. While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: September 30, 2024 (in millions) Prepaid and other current assets Other long-term assets Total Derivative Assets Other current liabilities Other long-term obligations Total Derivative Liabilities Foreign currency exchange contracts designated as hedges $ 4 $ — $ 4 $ 34 $ 6 $ 40 Foreign currency exchange contracts not designated as hedges 3 — 3 9 — 9 Total derivatives presented gross on the Condensed Consolidated Balance Sheets $ 7 $ 49 Gross amounts not offset on the Condensed Consolidated Balance Sheets: Derivative financial instruments $ (7) $ (7) Cash collateral received / pledged — — Net amount (legal offset) $ — $ 42 December 31, 2023 (in millions) Prepaid and other current assets Other long-term assets Total Derivative Assets Other current liabilities Other long-term obligations Total Derivative Liabilities Foreign currency exchange contracts designated as hedges $ 6 $ — $ 6 $ 38 $ 7 $ 45 Foreign currency exchange contracts not designated as hedges 1 — 1 15 — 15 Total derivatives presented gross on the Condensed Consolidated Balance Sheets $ 7 $ 59 Gross amounts not offset on the Condensed Consolidated Balance Sheets: Derivative financial instruments $ (7) $ (7) Cash collateral received / pledged — — Net amount (legal offset) $ — $ 52 The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Derivatives designated as hedges: Net (loss) gain recognized in Accumulated other comprehensive income $ (70) $ 75 $ 23 $ 74 Net gain reclassified from Accumulated other comprehensive income into Product sales $ 14 $ 16 $ 19 $ 50 Derivatives not designated as hedges: Net (loss) gain recognized in Other (income) expense, net $ (2) $ (4) $ 51 $ 46 The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income as of September 30, 2024 are expected to be reclassified to Product sales within 12 months. There were no discontinuances of cash flow hedges for the three and nine months ended September 30, 2024 and 2023. The cash flow effects of our derivative contracts for the nine months ended September 30, 2024 and 2023 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.

ACQUISITIONS, COLLABORATIONS AN

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS	9 Months Ended
	Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS	ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS We enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the research, development and commercialization of certain products and product candidates. The collaborations involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. The financial terms of these arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments. Acquisitions CymaBay In March 2024, we completed the acquisition of CymaBay Therapeutics, Inc. (“CymaBay”) for total consideration of $3.9 billion, net of cash acquired. Upon closing, CymaBay became our wholly-owned subsidiary. We accounted for this transaction as an asset acquisition since the lead asset, seladelpar, an investigational, oral, peroxisome proliferator-activated receptor delta agonist shown to regulate critical metabolic and liver disease pathways, represented substantially all of the fair value of the gross assets acquired. During the three months ended March 31, 2024, we recorded a $3.9 billion charge, representing an acquired IPR&D asset with no alternative future use, to Acquired in-process research and development expenses, as well as share-based compensation expense of $133 million related to the cash settlement of unvested CymaBay employee stock awards attributable to post-acquisition services, with $67 million being recorded in Research and development expenses and $67 million in Selling, general and administrative expenses on our Condensed Consolidated Statements of Operations. In connection with this acquisition, we recorded $263 million of assets acquired, primarily consisting of deferred tax assets, and $228 million of liabilities assumed, primarily related to an assumed financing arrangement. During the three months ended June 30, 2024, we paid $101 million towards the assumed financing arrangement related to a change-of-control provision, and in August 2024, we paid $108 million to settle the remaining liability. In July 2024, we paid $320 million to Janssen Pharmaceutica NV to extinguish a future royalty obligation related to seladelpar, which was recorded to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations for the three months ended September 30, 2024. In August 2024, FDA granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (“UDCA”) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. XinThera In May 2023, we closed an agreement to acquire XinThera, Inc. (“XinThera”), a privately held biotechnology company focused on small molecule drugs to treat cancer and immunologic diseases, for approximately $200 million in cash consideration, net of cash acquired. As a result, XinThera became our wholly-owned subsidiary. We accounted for the transaction as an asset acquisition and recorded a $170 million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations during the three months ended June 30, 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed. Under the agreement, the former shareholders of XinThera are eligible to receive performance-based development and regulatory milestone payments of up to approximately $760 million, with the first $50 million of such milestones paid and charged primarily to Acquired in-process research and development expenses in October 2023. Tmunity In February 2023, we closed an agreement to acquire Tmunity Therapeutics, Inc. (“Tmunity”), a clinical-stage, private biotechnology company focused on next-generation chimeric antigen receptor (“CAR”) T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $300 million in cash consideration. As a result, Tmunity became our wholly-owned subsidiary. We accounted for the transaction as an asset acquisition and recorded a $244 million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations during the three months ended March 31, 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed, consisting primarily of deferred tax assets. Under the agreement, the former shareholders of Tmunity and the University of Pennsylvania are eligible to receive a mix of up to approximately $1.0 billion in potential future payments upon achievement of certain development, regulatory and sales-based milestones, as well as royalty payments on sales, with the first $25 million of milestones charged to Acquired in-process research and development expenses in 2023 and paid in January 2024. During the three months ended September 30, 2024, we paid an additional $47 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations. Collaborations and Other Arrangements Arcellx In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, a public company, to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future next-generation autologous and non-autologous products. In December 2023, we expanded the scope of the collaboration to include lymphomas and exercised our option to negotiate a license for Arcellx’s ARC-SparX program, ACLX-001, in multiple myeloma. In conjunction with these collaboration agreements, we recorded a $212 million charge and a $101 million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and December 31, 2023, respectively, primarily related to upfront payments, as well as a combined equity investment of $299 million. Our equity investment is subject to lock-up provisions until June 2025 and is included in Prepaid and other current assets as of September 30, 2024. The companies will share development, clinical trial and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales. Arcellx is eligible to receive performance-based development and regulatory milestone payments of up to $1.5 billion related to CART-ddBCMA, a potential future next-generation autologous product and a potential future non-autologous product, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote the future products. During the three months ended September 30, 2024, we paid $68 million for development milestones met, which was charged to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts in to co-promote these additional future products as well. Arcus In January 2024, we amended our collaboration agreement with Arcus whereby we acquired approximately 15.2 million additional shares of Arcus common stock at a premium for $320 million, increasing our ownership to 30.1 million shares, or 33% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. We recorded $233 million for the fair value of the equity investment in Prepaid and other current assets on our Condensed Consolidated Balance Sheets and $87 million for the premium in Other (income) expense, net on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2024. We also recorded a charge for the $100 million fourth anniversary option continuation fee under the amended agreement to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2024. During the three months ended September 30, 2024, we paid the continuation fee, which was included in Net cash used in investing activities on our Condensed Consolidated Statements of Cash Flows. Our number of designees on Arcus’ board of directors was also increased to three.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS The following table summarizes our Intangible assets, net: September 30, 2024 December 31, 2023 (in millions) Gross Accumulated Foreign Currency Translation Adjustment Net Gross Accumulated Foreign Currency Translation Adjustment Net Finite-lived assets: Intangible asset – sofosbuvir $ 10,720 $ (7,574) $ — $ 3,146 $ 10,720 $ (7,050) $ — $ 3,670 Intangible asset – axicabtagene ciloleucel 7,110 (2,619) — 4,491 7,110 (2,314) — 4,796 Intangible asset – Trodelvy 11,730 (2,813) — 8,917 11,730 (2,002) — 9,728 Intangible asset – Hepcludex 845 (308) — 537 845 (243) — 602 Other 1,474 (911) 1 565 1,414 (827) 1 588 Total finite-lived assets 31,879 (14,224) 1 17,656 31,819 (12,436) 1 19,384 Indefinite-lived assets – IPR&D (1) 2,890 — — 2,890 7,070 — — 7,070 Total intangible assets $ 34,769 $ (14,224) $ 1 $ 20,546 $ 38,889 $ (12,436) $ 1 $ 26,454 _______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairments” below for 2024 activity. The Indefinite-lived assets – IPR&D balance as of September 30, 2024 was comprised of $1.8 billion related to SG for NSCLC and $1.1 billion related to bulevirtide. Impairment Assessments No intangible asset-related indicators of impairment were noted for the three and nine months ended September 30, 2024 and 2023, except as described under “2024 IPR&D Impairments” below. In October 2024, we announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy for treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. We have analyzed the implications of this and determined that it will not have an impact on the carrying amount of our finite-lived intangible asset related to Trodelvy. 2024 IPR&D Impairments In January 2024, we received data from our Phase 3 EVOKE-01 study of Trodelvy evaluating SG indicating that the study did not meet its primary endpoint of overall survival in previously treated metastatic NSCLC, thus triggering a review for potential impairment of the NSCLC IPR&D intangible asset. Based on our evaluation of the study results and all other data currently available, and in connection with the preparation of the financial statements for the first quarter, we performed an interim impairment test and determined that the revised estimated fair value of the NSCLC IPR&D intangible asset was below its carrying value. As a result, we recognized a partial impairment charge of $2.4 billion in In-process research and development impairment on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2024. In September 2024, based on discussions with regulators and external opinion leaders and the completed evaluation of the Phase 3 EVOKE-01 study data, we made a strategic decision to discontinue our clinical development program in metastatic NSCLC for Trodelvy in the second-line indication. This decision triggered a review for potential impairment of the NSCLC IPR&D intangible asset. Based on our evaluation, and in connection with the preparation of the financial statements for the third quarter, we performed an interim impairment test and determined that the revised estimated fair value of the NSCLC IPR&D intangible asset was below its carrying value. As a result, we recognized a partial impairment charge of $1.8 billion in In-process research and development impairment on our Condensed Consolidated Statements of Operations for the three months ended September 30, 2024. To arrive at the revised estimated fair values as of March 31, 2024 and September 30, 2024, we used a probability-weighted income approach that discounts expected future cash flows to present value, which requires the use of Level 3 fair value measurements and inputs, and requires the use of critical estimated inputs, including: revenues and operating profits related to the planned utilization of SG in NSCLC, which includes inputs such as addressable patient population, projected market share, treatment duration, and the life of the potential commercialized product; the probability of technical and regulatory success; the time and resources needed to complete the development and approval of SG in NSCLC; an appropriate discount rate based on the estimated weighted-average cost of capital for companies with profiles similar to our profile; and risks related to the viability of and potential alternative treatments in any future target markets. We used a discount rate of 7.00% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours. The revised estimated fair value of the NSCLC IPR&D intangible asset was $3.5 billion as of March 31, 2024 and $1.8 billion as of September 30, 2024.

OTHER FINANCIAL INFORMATION

OTHER FINANCIAL INFORMATION	9 Months Ended
	Sep. 30, 2024
Other Financial Information [Abstract]
OTHER FINANCIAL INFORMATION	OTHER FINANCIAL INFORMATION Accounts Receivable, Net The following table summarizes our Accounts receivable, net: (in millions) September 30, 2024 December 31, 2023 Accounts receivable $ 5,462 $ 5,495 Less: allowances for chargebacks 722 679 Less: allowances for cash discounts and other 89 101 Less: allowances for credit losses 65 56 Accounts receivable, net $ 4,587 $ 4,660 The majority of our trade accounts receivable arises from product sales in the U.S. and Europe. Inventories The following table summarizes our Inventories: (in millions) September 30, 2024 December 31, 2023 Raw materials $ 1,332 $ 1,246 Work in process 684 847 Finished goods 1,419 1,272 Total $ 3,435 $ 3,366 Reported as: Inventories $ 1,869 $ 1,787 Other long-term assets (1) 1,566 1,578 Total $ 3,435 $ 3,366 _______________________________ (1) Amounts primarily consist of raw materials. Other Current Liabilities The following table summarizes the components of Other current liabilities: (in millions) September 30, 2024 December 31, 2023 Compensation and employee benefits $ 1,051 $ 1,201 Income taxes payable 1,536 1,208 Allowance for sales returns 321 387 Other 1,988 2,334 Other current liabilities $ 4,896 $ 5,130 Accumulated Other Comprehensive Income The following tables summarize the changes in Accumulated other comprehensive income by component, net of tax: (in millions) Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax Total Balance as of December 31, 2023 $ 62 $ (5) $ (29) $ 28 Net unrealized gain 38 — 20 58 Reclassifications to net income — 5 (17) (12) Net current period other comprehensive income 38 5 3 45 Balance as of September 30, 2024 $ 100 $ — $ (27) $ 73 (in millions) Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax Total Balance as of December 31, 2022 $ 2 $ (33) $ 33 $ 2 Net unrealized (loss) gain (3) 10 65 72 Reclassifications to net income — 2 (44) (42) Net current period other comprehensive (loss) income (3) 11 21 30 Balance as of September 30, 2023 $ (1) $ (22) $ 54 $ 31 Restructuring During the three and nine months ended September 30, 2024, we incurred restructuring charges of $28 million and $112 million, respectively, primarily related to the initiation of reductions in our commercial and research and development workforce. We recorded $5 million and $68 million of these charges in Research and development expenses and $23 million and $45 million of these charges in Selling, general and administrative expenses on our Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2024, respectively.

DEBT AND CREDIT FACILITIES

DEBT AND CREDIT FACILITIES	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
DEBT AND CREDIT FACILITIES	DEBT AND CREDIT FACILITIES The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate September 30, 2024 December 31, 2023 Senior Unsecured March 2014 April 2024 3.70% $ — $ 1,750 Senior Unsecured November 2014 February 2025 3.50% 1,750 1,749 Senior Unsecured September 2015 March 2026 3.65% 2,746 2,744 Senior Unsecured September 2016 March 2027 2.95% 1,248 1,248 Senior Unsecured September 2020 October 2027 1.20% 748 747 Senior Unsecured September 2020 October 2030 1.65% 995 994 Senior Unsecured September 2023 October 2033 5.25% 993 992 Senior Unsecured September 2015 September 2035 4.60% 994 993 Senior Unsecured September 2016 September 2036 4.00% 743 743 Senior Unsecured September 2020 October 2040 2.60% 989 988 Senior Unsecured December 2011 December 2041 5.65% 996 996 Senior Unsecured March 2014 April 2044 4.80% 1,737 1,737 Senior Unsecured November 2014 February 2045 4.50% 1,735 1,734 Senior Unsecured September 2015 March 2046 4.75% 2,223 2,222 Senior Unsecured September 2016 March 2047 4.15% 1,730 1,729 Senior Unsecured September 2020 October 2050 2.80% 1,479 1,478 Senior Unsecured September 2023 October 2053 5.55% 988 988 Total senior unsecured notes 22,094 23,834 Liability related to future royalties 1,155 1,153 Total debt, net 23,249 24,987 Less: Current portion of long-term debt, net 1,812 1,798 Total Long-term debt, net $ 21,437 $ 23,189 Senior Unsecured Notes In April 2024, we repaid at maturity $1.75 billion of principal balance related to our senior unsecured notes. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of September 30, 2024, we were not in violation of any covenants. Credit Facilities In June 2024, we terminated our $2.5 billion revolving credit facility maturing in June 2025 (the “2020 Revolving Credit Facility”) and entered into a new $2.5 billion revolving credit facility maturing in June 2029 (the “2024 Revolving Credit Facility”), which has terms substantially similar to the 2020 Revolving Credit Facility. The 2024 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of September 30, 2024 and December 31, 2023, there were no amounts outstanding under these revolving credit facilities. The 2024 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. At September 30, 2024, we were in compliance with all covenants. Loans under the 2024 Revolving Credit Facility bear interest at either (i) Term SOFR plus the Applicable Percentage, (ii) the Alternative Currency Term Rate plus the Applicable Percentage, or (iii) the Base Rate plus the Applicable Percentage, each as defined in the 2024 Revolving Credit Facility agreement. We may terminate or reduce the commitments and may prepay any loans under the 2024 Revolving Credit Facility in whole or in part at any time without premium or penalty.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Proceedings We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. We did not have any material accruals for the matters described herein on our Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023. Litigation Relating to Pre-Exposure Prophylaxis In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, “HHS Patents”) by the Patent Trial and Appeal Board (“PTAB”). The HHS Patents are assigned to the U.S. Department of Health and Human Services (“HHS”) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (“TDF”) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (“PrEP”). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the use of Truvada and Descovy for PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a lawsuit against the U.S. federal government in the U.S. Court of Federal Claims (“CFC”), alleging breach of three material transfer agreements (“MTAs”) related to the research underlying the HHS Patents and two clinical trial agreements (“CTAs”) by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the CFC was held in June 2022, and in November 2022, the CFC determined that the government breached the MTAs. In January 2024, the CFC found the government liable for breach of both CTAs. A separate trial at the CFC to determine the damages we are owed based on the government’s breaches has been scheduled for March 2025. In May 2023, the District Court held a trial regarding the government’s patent infringement claims, and the jury rendered a full defense verdict in favor of Gilead, finding that the asserted claims of the HHS Patents are invalid and the HHS patents are not infringed. In March 2024, the District Court upheld the jury’s verdict that the government’s patents are invalid, denied the government’s request for a new trial and then entered final judgment. In July 2024, the government filed a notice of appeal. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached its contracts with Gilead, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada’s use for PrEP and post-exposure prophylaxis because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. Litigation with Generic Manufacturers As part of the approval process for some of our products, FDA granted us a New Chemical Entity (“NCE”) exclusivity period during which other manufacturers’ applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (“ANDA”), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product’s approval. In October 2021, we received a letter from Lupin Ltd. (“Lupin”) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen and Janssen Products, L.P., filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (“Apotex”) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen and Janssen Products, L.P., filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. The cases against Lupin and Apotex have been consolidated into a single trial scheduled for February 2025. Starting in March 2022, we received letters from Lupin, Laurus Labs (“Laurus”) and Cipla Ltd. (“Cipla”), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of the adult dosage strength of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of four of the six patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware and intend to enforce and defend our intellectual property. Additionally, in November 2023, we received a letter from Cipla indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of the pediatric dosage strength of Biktarvy. Cipla challenged the validity of two of the patents listed in the Orange Book as associated with Biktarvy. We filed a separate lawsuit against Cipla in December 2023 in the U.S. District Court of Delaware. This lawsuit has been consolidated with the first lawsuit, with a single trial scheduled for October 2025. In October 2024, Cipla separately filed a petition at the U.S. Patent & Trademark Office (USPTO) for Inter Partes Review (IPR) of one of the patents at issue in District Court litigation. We intend to defend this patent at the USPTO. In June 2023, we received a letter from Apotex indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Genvoya. In July 2023, we filed a patent infringement lawsuit against Apotex in the U.S. District Court of Delaware and intend to enforce and defend our intellectual property. This case has been consolidated with the Symtuza matters discussed above, and a trial has been scheduled for February 2025. Antitrust and Consumer Protection We, along with Bristol-Myers Squibb Company (“BMS”), Johnson & Johnson, Inc. (“Johnson & Johnson”), and Teva Pharmaceutical Industries Ltd. (“Teva”) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs consisting of retail pharmacies, individual health plans and United Healthcare, filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the classes. These cases have been coordinated with the class actions. In March 2023, the District Court granted our motion to hold separate trials as to (i) the allegations against us and Teva seeking monetary damages relating to Truvada and Atripla (“Phase I”) and (ii) the allegations against us and, in part, Johnson & Johnson, seeking monetary damages and injunctive relief relating to Complera (“Phase II”). In May 2023, we settled claims with the direct purchaser class and the retailer opt-out plaintiffs for $525 million, which we paid in the second half of 2023. The settlement agreements are not an admission of liability or fault by us. In June 2023, the jury returned a complete verdict in Gilead’s favor on the remaining plaintiffs’ Phase I allegations. In November 2023, the court denied plaintiffs’ motion to set aside the verdict, and in February 2024, the court entered final judgment on the Phase I verdict and certain summary judgment rulings. In September 2024, plaintiffs filed their opening appellate briefs challenging the Phase I verdict and those summary judgment rulings. The court has stayed Phase II pending the appeal of Phase I. While we intend to vigorously oppose the appeal and defend against the Phase II claims, we cannot predict the ultimate outcome. If plaintiffs are successful in their appeal or Phase II claims, we could be required to pay monetary damages or could be subject to permanent injunctive relief in favor of plaintiffs. In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief. In March 2024, the court denied our motion for judgment on the pleadings to preclude Aetna from re-litigating claims that were dismissed at summary judgment in the above class action cases. We filed a writ petition appealing the denial of our motion for judgment on the pleadings, which the appellate court denied in May 2024. In April 2024, the court granted our motion to bifurcate the case to adjudicate the issue of preclusion before litigating the merits of the case. In July 2024, Aetna filed a request to voluntarily dismiss two of its claims with prejudice, which the court subsequently granted, leaving only the claims related to Truvada and Atripla. In September 2024, Aetna filed an amended complaint with respect to these claims. In February 2021, we, along with BMS and Teva, were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief. We moved to dismiss the case based on lack of personal jurisdiction and, in July 2023, the New Mexico Supreme Court remanded the case back to the trial court for limited jurisdictional discovery. We intend to vigorously defend ourselves in these actions, however, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs, which may result in a material, adverse effect on our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable. Product Liability We have been named as a defendant in one putative class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California and Missouri, involve approximately 25,000 active plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022 but is currently stayed pending the conclusion of appellate proceedings in the California Supreme Court. A bellwether trial date in California federal court has been vacated following a settlement agreement in principle. Specifically, Gilead reached an agreement to make a one-time payment of up to $40 million to a group of eligible plaintiffs (approximately 2,625 plaintiffs). The agreement is subject to certain conditions, including that at least 98% of eligible plaintiffs elect to participate in the settlement. The putative class action in Missouri is currently awaiting decision from the court whether to certify the proposed class. We intend to vigorously defend ourselves in these actions, however, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages, which may result in a material, adverse effect on our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable. Government Investigation In 2017, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry. Qui Tam Litigation A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government’s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead’s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The lawsuit seeks all available relief under these statutes. Health Choice Advocates, LLC (“Health Choice”) filed a qui tam lawsuit against Gilead in May 2020 in Texas state court. The lawsuit alleged that Gilead violated the Texas Medicare Fraud Prevention Act (“TMFPA”) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient support programs. The lawsuit sought all available relief under the TMFPA. Health Choice voluntarily dismissed the case without prejudice in August 2023, and commenced a new action in October 2023, asserting largely identical allegations and claims. In the newly filed action, the Texas Attorney General has intervened as a plaintiff. We intend to vigorously defend ourselves in these actions, however, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages, which may result in a material, adverse effect on our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable. Other Matters We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that it is probable or reasonably possible that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE The following table shows the calculation of Basic and Diluted earnings (loss) per share attributable to Gilead: Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share amounts) 2024 2023 2024 2023 Net income (loss) attributable to Gilead $ 1,253 $ 2,180 $ (1,303) $ 4,236 Shares used in basic earnings (loss) per share attributable to Gilead calculation 1,247 1,248 1,247 1,249 Dilutive effect of stock options and equivalents 7 8 — 10 Shares used in diluted earnings (loss) per share attributable to Gilead calculation 1,254 1,257 1,247 1,259 Basic earnings (loss) per share attributable to Gilead $ 1.00 $ 1.75 $ (1.04) $ 3.39 Diluted earnings (loss) per share attributable to Gilead $ 1.00 $ 1.73 $ (1.04) $ 3.37 Potential shares of common stock excluded from the computation of Diluted earnings (loss) per share attributable to Gilead because their effect would have been antidilutive were 7 million and 14 million for the three and nine months ended September 30, 2024, respectively, and 6 million and 4 million for the three and nine months ended September 30, 2023, respectively.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The following table summarizes our Income tax (benefit) expense: Three Months Ended Nine Months Ended September 30, September 30, (in millions, except percentages) 2024 2023 2024 2023 Income (loss) before income taxes $ 956 $ 2,318 $ (1,477) $ 5,206 Income tax (benefit) expense $ (297) $ 146 $ (174) $ 1,010 Effective tax rate (31.1) % 6.3 % 11.8 % 19.4 % Our effective income tax rate of (31.1)% for the three months ended September 30, 2024 differed from the U.S. federal statutory rate of 21% primarily due to a non-recurring tax benefit associated with a legal entity restructuring and a decrease in state deferred tax liabilities associated with the $1.8 billion NSCLC IPR&D intangible asset impairment charge. Our effective income tax rate of 11.8% for the nine months ended September 30, 2024 differed from the U.S. federal statutory rate of 21% primarily due to $3.9 billion of non-deductible acquired IPR&D expense recorded in connection with our acquisition of CymaBay, partially offset by a non-recurring tax benefit associated with a legal entity restructuring, a decrease in state deferred tax liabilities associated with the $4.2 billion NSCLC IPR&D intangible asset impairment charge, and settlements with tax authorities. Our effective income tax rate of 6.3% for the three months ended September 30, 2023 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in unrecognized tax benefits as a result of reaching agreement with a tax authority on certain tax positions. Our effective income tax rate of 19.4% for the nine months ended September 30, 2023 differed from the U.S. federal statutory rate of 21% primarily due to the above-mentioned reason for the three months ended September 30, 2023, partially offset by remeasurement of certain deferred tax liabilities related to acquired intangible assets and non-deductible acquired IPR&D expenses recorded associated with our acquisitions of XinThera and Tmunity. Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service for our 2019 to 2021 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues on the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions. During the nine months ended September 30, 2024, our unrecognized tax benefits balance as of December 31, 2023 increased by approximately $200 million. This net increase was primarily due to an increase of approximately $700 million for current year unrecognized tax benefits, partially offset by a decrease of approximately $500 million for reductions to prior year tax positions and settlements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net income (loss) attributable to Gilead	$ 1,253	$ 2,180	$ (1,303)	$ 4,236

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Merdad V. Parsey [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On August 28, 2024, Merdad V. Parsey, M.D., Ph.D., our Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell, subject to certain conditions, through April 8, 2025: (a) up to 395,164 shares of our common stock; and (b) 40% of the net vested shares of our common stock to be issued to Dr. Parsey in connection with the potential vesting and settlement of certain performance stock units.
Name	Merdad V. Parsey
Title	Chief Medical Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 28, 2024
Expiration Date	April 8, 2025
Arrangement Duration	223 days
Aggregate Available	395,164	395,164
Andrew Dickinson [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On August 29, 2024, Andrew Dickinson, our Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act to sell up to 695,164 shares of our common stock through November 29, 2026, subject to certain conditions.
Name	Andrew Dickinson
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 29, 2024
Expiration Date	November 29, 2026
Arrangement Duration	822 days
Aggregate Available	695,164	695,164

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (“Gilead,” “we,” “our” or “us”) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2023, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2024, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03 “Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” ASU 2024-03 requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 annual report to be filed in early 2028 and all quarterly and annual reports thereafter. We expect the adoption of this standard to result in increased disclosures in our Notes to Consolidated Financial Statements.
Fair Value Measurements	Level 2 Inputs Available-for-Sale Debt Securities For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. Foreign Currency Derivative Contracts Our foreign currency derivative contracts have maturities of 18 months or less and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P Global Ratings, Moody’s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by utilizing an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate (“SOFR”) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals. Level 3 Inputs Contingent Consideration Liability In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to €300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (“FDA”) approval of Hepcludex until the related contingency is resolved.

REVENUES (Tables)

REVENUES (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Summary of Total Revenues	The following table summarizes our Total revenues: Three Months Ended September 30, 2024 Three Months Ended September 30, 2023 (in millions) U.S. Europe Rest of World Total U.S. Europe Rest of World Total Product sales: HIV Biktarvy $ 2,826 $ 375 $ 272 $ 3,472 $ 2,504 $ 313 $ 268 $ 3,085 Descovy 534 24 28 586 460 25 26 511 Genvoya 384 44 21 449 433 47 23 503 Odefsey 248 69 9 326 257 74 11 343 Symtuza - Revenue share (1) 103 33 3 139 96 32 3 131 Other HIV (2) 65 26 9 100 56 28 9 94 Total HIV 4,161 570 342 5,073 3,807 519 341 4,667 Liver Disease Sofosbuvir/Velpatasvir (3) 222 67 96 385 215 76 85 377 Vemlidy 126 11 95 232 112 9 106 228 Other Liver Disease (4) 45 54 17 116 49 33 20 102 Total Liver Disease 393 132 207 733 376 119 211 706 Veklury 393 81 219 692 258 65 313 636 Oncology Cell Therapy Tecartus 63 29 6 98 64 27 4 96 Yescarta 145 182 60 387 197 154 40 391 Total Cell Therapy 208 211 66 485 261 181 45 486 Trodelvy 226 80 26 332 201 62 21 283 Total Oncology 433 291 92 816 462 243 65 769 Other AmBisome 6 71 52 130 12 63 39 115 Other (5) 47 8 16 71 69 9 23 101 Total Other 53 80 68 201 82 72 62 216 Total product sales 5,433 1,154 928 7,515 4,985 1,017 992 6,994 Royalty, contract and other revenues 17 13 1 30 32 23 1 56 Total revenues $ 5,450 $ 1,167 $ 929 $ 7,545 $ 5,017 $ 1,040 $ 993 $ 7,051 Nine Months Ended September 30, 2024 Nine Months Ended September 30, 2023 (in millions) U.S. Europe Rest of World Total U.S. Europe Rest of World Total Product sales: HIV Biktarvy $ 7,726 $ 1,110 $ 814 $ 9,649 $ 7,104 $ 920 $ 717 $ 8,741 Descovy 1,339 75 82 1,496 1,314 75 86 1,475 Genvoya 1,088 138 66 1,292 1,305 157 81 1,544 Odefsey 705 217 30 952 754 223 33 1,011 Symtuza - Revenue share (1) 338 101 9 448 278 101 10 390 Other HIV (2) 190 96 36 322 192 91 38 321 Total HIV 11,386 1,737 1,038 14,160 10,949 1,568 965 13,482 Liver Disease Sofosbuvir/Velpatasvir (3) 737 230 299 1,266 643 250 266 1,159 Vemlidy 338 33 328 699 295 28 322 645 Other Liver Disease (4) 134 148 55 337 113 112 64 289 Total Liver Disease 1,210 411 682 2,302 1,051 390 652 2,093 Veklury 784 204 473 1,461 607 227 630 1,465 Oncology Cell Therapy Tecartus 181 102 22 305 179 83 11 272 Yescarta 502 509 170 1,181 624 408 99 1,130 Total Cell Therapy 683 611 192 1,485 802 491 109 1,402 Trodelvy 655 217 88 960 551 169 44 764 Total Oncology 1,338 828 280 2,446 1,354 660 153 2,167 Other AmBisome 37 210 176 424 39 192 150 381 Other (5) 203 26 52 281 197 31 49 277 Total Other 241 236 228 705 236 224 199 658 Total product sales 14,958 3,416 2,700 21,074 14,196 3,069 2,599 19,864 Royalty, contract and other revenues 66 43 2 111 57 77 4 138 Total revenues $ 15,024 $ 3,459 $ 2,703 $ 21,185 $ 14,253 $ 3,146 $ 2,603 $ 20,002 _______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). (2) Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods	The following table summarizes revenues recognized from performance obligations satisfied in prior years: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Revenue share with Janssen and royalties for licenses of intellectual property $ 173 $ 166 $ 545 $ 517 Changes in estimates $ 146 $ 111 $ 388 $ 347
Summary of Contract Balances	The following table summarizes our contract balances: (in millions) September 30, 2024 December 31, 2023 Contract assets $ 184 $ 117 Contract liabilities $ 68 $ 109

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: September 30, 2024 December 31, 2023 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Available-for-sale debt securities (1) : U.S. treasury securities $ — $ — $ — $ — $ 426 $ — $ — $ 426 U.S. government agencies securities — — — — — 127 — 127 Non-U.S. government securities — — — — — 10 — 10 Certificates of deposit — — — — — 45 — 45 Corporate debt securities — — — — — 1,451 — 1,451 Residential mortgage and asset-backed securities — — — — — 367 — 367 Equity securities: Money market funds 3,502 — — 3,502 4,465 — — 4,465 Publicly traded equity securities (2) 1,665 — — 1,665 1,458 — — 1,458 Deferred compensation plan 343 — — 343 284 — — 284 Foreign currency derivative contracts — 7 — 7 — 7 — 7 Total $ 5,510 $ 7 $ — $ 5,517 $ 6,633 $ 2,007 $ — $ 8,639 Liabilities: Liability for MYR GmbH (“MYR”) contingent consideration $ — $ — $ 222 $ 222 $ — $ — $ 228 $ 228 Deferred compensation plan 343 — — 343 283 — — 283 Foreign currency derivative contracts — 49 — 49 — 59 — 59 Total $ 343 $ 49 $ 222 $ 615 $ 283 $ 59 $ 228 $ 570 _______________________________ (1) During the three months ended March 31, 2024, we sold all of our available-for-sale debt securities and used the proceeds to partially fund our acquisition of CymaBay Therapeutics, Inc. (“CymaBay”) discussed in Note 6. Acquisitions, Collaborations and Other Arrangements. (2)
Summary of Total Estimated Fair Value and Carrying Value of Senior Unsecured Notes	The following table summarizes the total estimated fair value and carrying value of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values: (in millions) September 30, 2024 December 31, 2023 Fair value $ 20,931 $ 22,567 Carrying value $ 22,094 $ 23,834
Summary of Change in Fair Value of Contingent Consideration Liability	The following table summarizes the change in fair value of our contingent consideration liability: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Beginning balance $ 208 $ 288 $ 228 $ 275 Changes in valuation assumptions (1) 5 (2) (6) 3 Effect of foreign exchange remeasurement (2) 9 (11) 1 (4) Ending balance (3) $ 222 $ 275 $ 222 $ 275 ________________________________ (1) Included in Research and development expenses on our Condensed Consolidated Statements of Operations. The changes in 2024 and 2023 primarily related to changes in discount rates and assumptions around probability and timing of regulatory approval. (2) Included in Other (income) expense, net on our Condensed Consolidated Statements of Operations. (3) Included in Other long-term obligations on our Condensed Consolidated Balance Sheets.

AVAILABLE-FOR-SALE DEBT SECUR_2

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Securities, Available-for-Sale [Abstract]
Summary of Available-for-Sale Debt Securities	The following table summarizes our available-for-sale debt securities as of December 31, 2023: December 31, 2023 (in millions) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 427 $ — $ (1) $ 426 U.S. government agencies securities 127 — — 127 Non-U.S. government securities 10 — — 10 Certificates of deposit 45 — — 45 Corporate debt securities 1,455 4 (8) 1,451 Residential mortgage and asset-backed securities 366 1 — 367 Total $ 2,430 $ 5 $ (10) $ 2,426
Summary of Available-for-Sale Debt Securities Been in Continuous Unrealized Loss Position	The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time, as of December 31, 2023: December 31, 2023 Less Than 12 Months 12 Months or Longer Total (in millions) Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ — $ 161 $ (1) $ 48 $ (1) $ 209 U.S. government agencies securities — 106 — 2 — 108 Non-U.S. government securities — 5 — 5 — 10 Corporate debt securities (1) 333 (7) 546 (8) 878 Residential mortgage and asset-backed securities — 123 — 24 — 147 Total $ (2) $ 727 $ (8) $ 624 $ (10) $ 1,351
Summary of Classification of Available-for-Sale Debt Securities	The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets as of December 31, 2023: (in millions) December 31, 2023 Cash and cash equivalents $ 83 Short-term marketable debt securities 1,179 Long-term marketable debt securities 1,163 Total $ 2,426
Summary of Classification of Equity Securities	The following table summarizes the classification of our equity securities on our Condensed Consolidated Balance Sheets: (in millions) September 30, 2024 December 31, 2023 Equity securities measured at fair value: Cash and cash equivalents $ 3,502 $ 4,465 Prepaid and other current assets 1,660 1,086 Other long-term assets 348 656 Equity method investments and other equity investments without readily determinable fair values: Other long-term assets 382 $ 340 Total $ 5,892 $ 6,547
Summary of Net Unrealized Gains and Losses on Equity Securities	The following table summarizes net unrealized gains and losses on equity securities still held as of the respective balance sheet dates, included in Other (income) expense, net on our Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Unrealized (gain) loss, net $ (257) $ 128 $ 155 $ 249

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Classification and Fair Value of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: September 30, 2024 (in millions) Prepaid and other current assets Other long-term assets Total Derivative Assets Other current liabilities Other long-term obligations Total Derivative Liabilities Foreign currency exchange contracts designated as hedges $ 4 $ — $ 4 $ 34 $ 6 $ 40 Foreign currency exchange contracts not designated as hedges 3 — 3 9 — 9 Total derivatives presented gross on the Condensed Consolidated Balance Sheets $ 7 $ 49 Gross amounts not offset on the Condensed Consolidated Balance Sheets: Derivative financial instruments $ (7) $ (7) Cash collateral received / pledged — — Net amount (legal offset) $ — $ 42 December 31, 2023 (in millions) Prepaid and other current assets Other long-term assets Total Derivative Assets Other current liabilities Other long-term obligations Total Derivative Liabilities Foreign currency exchange contracts designated as hedges $ 6 $ — $ 6 $ 38 $ 7 $ 45 Foreign currency exchange contracts not designated as hedges 1 — 1 15 — 15 Total derivatives presented gross on the Condensed Consolidated Balance Sheets $ 7 $ 59 Gross amounts not offset on the Condensed Consolidated Balance Sheets: Derivative financial instruments $ (7) $ (7) Cash collateral received / pledged — — Net amount (legal offset) $ — $ 52
Summary of Effect of Derivative Contracts	The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2024 2023 2024 2023 Derivatives designated as hedges: Net (loss) gain recognized in Accumulated other comprehensive income $ (70) $ 75 $ 23 $ 74 Net gain reclassified from Accumulated other comprehensive income into Product sales $ 14 $ 16 $ 19 $ 50 Derivatives not designated as hedges: Net (loss) gain recognized in Other (income) expense, net $ (2) $ (4) $ 51 $ 46

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Finite-Lived Intangible Assets	The following table summarizes our Intangible assets, net: September 30, 2024 December 31, 2023 (in millions) Gross Accumulated Foreign Currency Translation Adjustment Net Gross Accumulated Foreign Currency Translation Adjustment Net Finite-lived assets: Intangible asset – sofosbuvir $ 10,720 $ (7,574) $ — $ 3,146 $ 10,720 $ (7,050) $ — $ 3,670 Intangible asset – axicabtagene ciloleucel 7,110 (2,619) — 4,491 7,110 (2,314) — 4,796 Intangible asset – Trodelvy 11,730 (2,813) — 8,917 11,730 (2,002) — 9,728 Intangible asset – Hepcludex 845 (308) — 537 845 (243) — 602 Other 1,474 (911) 1 565 1,414 (827) 1 588 Total finite-lived assets 31,879 (14,224) 1 17,656 31,819 (12,436) 1 19,384 Indefinite-lived assets – IPR&D (1) 2,890 — — 2,890 7,070 — — 7,070 Total intangible assets $ 34,769 $ (14,224) $ 1 $ 20,546 $ 38,889 $ (12,436) $ 1 $ 26,454 _______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairments” below for 2024 activity. The Indefinite-lived assets – IPR&D balance as of September 30, 2024 was comprised of $1.8 billion related to SG for NSCLC and $1.1 billion related to bulevirtide.
Summary of Indefinite-Lived Intangible Assets	The following table summarizes our Intangible assets, net: September 30, 2024 December 31, 2023 (in millions) Gross Accumulated Foreign Currency Translation Adjustment Net Gross Accumulated Foreign Currency Translation Adjustment Net Finite-lived assets: Intangible asset – sofosbuvir $ 10,720 $ (7,574) $ — $ 3,146 $ 10,720 $ (7,050) $ — $ 3,670 Intangible asset – axicabtagene ciloleucel 7,110 (2,619) — 4,491 7,110 (2,314) — 4,796 Intangible asset – Trodelvy 11,730 (2,813) — 8,917 11,730 (2,002) — 9,728 Intangible asset – Hepcludex 845 (308) — 537 845 (243) — 602 Other 1,474 (911) 1 565 1,414 (827) 1 588 Total finite-lived assets 31,879 (14,224) 1 17,656 31,819 (12,436) 1 19,384 Indefinite-lived assets – IPR&D (1) 2,890 — — 2,890 7,070 — — 7,070 Total intangible assets $ 34,769 $ (14,224) $ 1 $ 20,546 $ 38,889 $ (12,436) $ 1 $ 26,454 _______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairments” below for 2024 activity. The Indefinite-lived assets – IPR&D balance as of September 30, 2024 was comprised of $1.8 billion related to SG for NSCLC and $1.1 billion related to bulevirtide.

OTHER FINANCIAL INFORMATION (Ta

OTHER FINANCIAL INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2024
Other Financial Information [Abstract]
Summary of Accounts Receivable, Net	The following table summarizes our Accounts receivable, net: (in millions) September 30, 2024 December 31, 2023 Accounts receivable $ 5,462 $ 5,495 Less: allowances for chargebacks 722 679 Less: allowances for cash discounts and other 89 101 Less: allowances for credit losses 65 56 Accounts receivable, net $ 4,587 $ 4,660
Summary of Inventories	The following table summarizes our Inventories: (in millions) September 30, 2024 December 31, 2023 Raw materials $ 1,332 $ 1,246 Work in process 684 847 Finished goods 1,419 1,272 Total $ 3,435 $ 3,366 Reported as: Inventories $ 1,869 $ 1,787 Other long-term assets (1) 1,566 1,578 Total $ 3,435 $ 3,366 _______________________________ (1) Amounts primarily consist of raw materials.
Summary of Components of Other Current Liabilities	The following table summarizes the components of Other current liabilities: (in millions) September 30, 2024 December 31, 2023 Compensation and employee benefits $ 1,051 $ 1,201 Income taxes payable 1,536 1,208 Allowance for sales returns 321 387 Other 1,988 2,334 Other current liabilities $ 4,896 $ 5,130
Summary of Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in Accumulated other comprehensive income by component, net of tax: (in millions) Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax Total Balance as of December 31, 2023 $ 62 $ (5) $ (29) $ 28 Net unrealized gain 38 — 20 58 Reclassifications to net income — 5 (17) (12) Net current period other comprehensive income 38 5 3 45 Balance as of September 30, 2024 $ 100 $ — $ (27) $ 73 (in millions) Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax Total Balance as of December 31, 2022 $ 2 $ (33) $ 33 $ 2 Net unrealized (loss) gain (3) 10 65 72 Reclassifications to net income — 2 (44) (42) Net current period other comprehensive (loss) income (3) 11 21 30 Balance as of September 30, 2023 $ (1) $ (22) $ 54 $ 31

DEBT AND CREDIT FACILITIES (Tab

DEBT AND CREDIT FACILITIES (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Summary of Carrying Amount of Borrowings Under Various Financing Arrangements	The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate September 30, 2024 December 31, 2023 Senior Unsecured March 2014 April 2024 3.70% $ — $ 1,750 Senior Unsecured November 2014 February 2025 3.50% 1,750 1,749 Senior Unsecured September 2015 March 2026 3.65% 2,746 2,744 Senior Unsecured September 2016 March 2027 2.95% 1,248 1,248 Senior Unsecured September 2020 October 2027 1.20% 748 747 Senior Unsecured September 2020 October 2030 1.65% 995 994 Senior Unsecured September 2023 October 2033 5.25% 993 992 Senior Unsecured September 2015 September 2035 4.60% 994 993 Senior Unsecured September 2016 September 2036 4.00% 743 743 Senior Unsecured September 2020 October 2040 2.60% 989 988 Senior Unsecured December 2011 December 2041 5.65% 996 996 Senior Unsecured March 2014 April 2044 4.80% 1,737 1,737 Senior Unsecured November 2014 February 2045 4.50% 1,735 1,734 Senior Unsecured September 2015 March 2046 4.75% 2,223 2,222 Senior Unsecured September 2016 March 2047 4.15% 1,730 1,729 Senior Unsecured September 2020 October 2050 2.80% 1,479 1,478 Senior Unsecured September 2023 October 2053 5.55% 988 988 Total senior unsecured notes 22,094 23,834 Liability related to future royalties 1,155 1,153 Total debt, net 23,249 24,987 Less: Current portion of long-term debt, net 1,812 1,798 Total Long-term debt, net $ 21,437 $ 23,189

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Summary of the Calculation of Basic and Diluted Earnings (Loss) Per Share	The following table shows the calculation of Basic and Diluted earnings (loss) per share attributable to Gilead: Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share amounts) 2024 2023 2024 2023 Net income (loss) attributable to Gilead $ 1,253 $ 2,180 $ (1,303) $ 4,236 Shares used in basic earnings (loss) per share attributable to Gilead calculation 1,247 1,248 1,247 1,249 Dilutive effect of stock options and equivalents 7 8 — 10 Shares used in diluted earnings (loss) per share attributable to Gilead calculation 1,254 1,257 1,247 1,259 Basic earnings (loss) per share attributable to Gilead $ 1.00 $ 1.75 $ (1.04) $ 3.39 Diluted earnings (loss) per share attributable to Gilead $ 1.00 $ 1.73 $ (1.04) $ 3.37

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Summary of Income Tax (Benefit) Expense	The following table summarizes our Income tax (benefit) expense: Three Months Ended Nine Months Ended September 30, September 30, (in millions, except percentages) 2024 2023 2024 2023 Income (loss) before income taxes $ 956 $ 2,318 $ (1,477) $ 5,206 Income tax (benefit) expense $ (297) $ 146 $ (174) $ 1,010 Effective tax rate (31.1) % 6.3 % 11.8 % 19.4 %

REVENUES - Summary of Total Rev

REVENUES - Summary of Total Revenues (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Total revenues	$ 7,545	$ 7,051	$ 21,185	$ 20,002
U.S.
Disaggregation of Revenue [Line Items]
Total revenues	5,450	5,017	15,024	14,253
Europe
Disaggregation of Revenue [Line Items]
Total revenues	1,167	1,040	3,459	3,146
Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	929	993	2,703	2,603
Total product sales
Disaggregation of Revenue [Line Items]
Total revenues	7,515	6,994	21,074	19,864
Total product sales | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	5,433	4,985	14,958	14,196
Total product sales | Europe
Disaggregation of Revenue [Line Items]
Total revenues	1,154	1,017	3,416	3,069
Total product sales | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	928	992	2,700	2,599
Total HIV
Disaggregation of Revenue [Line Items]
Total revenues	5,073	4,667	14,160	13,482
Total HIV | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	4,161	3,807	11,386	10,949
Total HIV | Europe
Disaggregation of Revenue [Line Items]
Total revenues	570	519	1,737	1,568
Total HIV | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	342	341	1,038	965
Biktarvy
Disaggregation of Revenue [Line Items]
Total revenues	3,472	3,085	9,649	8,741
Biktarvy | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	2,826	2,504	7,726	7,104
Biktarvy | Europe
Disaggregation of Revenue [Line Items]
Total revenues	375	313	1,110	920
Biktarvy | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	272	268	814	717
Descovy
Disaggregation of Revenue [Line Items]
Total revenues	586	511	1,496	1,475
Descovy | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	534	460	1,339	1,314
Descovy | Europe
Disaggregation of Revenue [Line Items]
Total revenues	24	25	75	75
Descovy | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	28	26	82	86
Genvoya
Disaggregation of Revenue [Line Items]
Total revenues	449	503	1,292	1,544
Genvoya | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	384	433	1,088	1,305
Genvoya | Europe
Disaggregation of Revenue [Line Items]
Total revenues	44	47	138	157
Genvoya | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	21	23	66	81
Odefsey
Disaggregation of Revenue [Line Items]
Total revenues	326	343	952	1,011
Odefsey | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	248	257	705	754
Odefsey | Europe
Disaggregation of Revenue [Line Items]
Total revenues	69	74	217	223
Odefsey | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	9	11	30	33
Symtuza - Revenue share
Disaggregation of Revenue [Line Items]
Total revenues	139	131	448	390
Symtuza - Revenue share | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	103	96	338	278
Symtuza - Revenue share | Europe
Disaggregation of Revenue [Line Items]
Total revenues	33	32	101	101
Symtuza - Revenue share | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	3	3	9	10
Other HIV
Disaggregation of Revenue [Line Items]
Total revenues	100	94	322	321
Other HIV | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	65	56	190	192
Other HIV | Europe
Disaggregation of Revenue [Line Items]
Total revenues	26	28	96	91
Other HIV | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	9	9	36	38
Total Liver Disease
Disaggregation of Revenue [Line Items]
Total revenues	733	706	2,302	2,093
Total Liver Disease | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	393	376	1,210	1,051
Total Liver Disease | Europe
Disaggregation of Revenue [Line Items]
Total revenues	132	119	411	390
Total Liver Disease | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	207	211	682	652
Sofosbuvir/Velpatasvir
Disaggregation of Revenue [Line Items]
Total revenues	385	377	1,266	1,159
Sofosbuvir/Velpatasvir | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	222	215	737	643
Sofosbuvir/Velpatasvir | Europe
Disaggregation of Revenue [Line Items]
Total revenues	67	76	230	250
Sofosbuvir/Velpatasvir | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	96	85	299	266
Vemlidy
Disaggregation of Revenue [Line Items]
Total revenues	232	228	699	645
Vemlidy | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	126	112	338	295
Vemlidy | Europe
Disaggregation of Revenue [Line Items]
Total revenues	11	9	33	28
Vemlidy | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	95	106	328	322
Other Liver Disease
Disaggregation of Revenue [Line Items]
Total revenues	116	102	337	289
Other Liver Disease | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	45	49	134	113
Other Liver Disease | Europe
Disaggregation of Revenue [Line Items]
Total revenues	54	33	148	112
Other Liver Disease | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	17	20	55	64
Veklury
Disaggregation of Revenue [Line Items]
Total revenues	692	636	1,461	1,465
Veklury | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	393	258	784	607
Veklury | Europe
Disaggregation of Revenue [Line Items]
Total revenues	81	65	204	227
Veklury | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	219	313	473	630
Total Oncology
Disaggregation of Revenue [Line Items]
Total revenues	816	769	2,446	2,167
Total Oncology | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	433	462	1,338	1,354
Total Oncology | Europe
Disaggregation of Revenue [Line Items]
Total revenues	291	243	828	660
Total Oncology | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	92	65	280	153
Total Cell Therapy
Disaggregation of Revenue [Line Items]
Total revenues	485	486	1,485	1,402
Total Cell Therapy | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	208	261	683	802
Total Cell Therapy | Europe
Disaggregation of Revenue [Line Items]
Total revenues	211	181	611	491
Total Cell Therapy | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	66	45	192	109
Tecartus
Disaggregation of Revenue [Line Items]
Total revenues	98	96	305	272
Tecartus | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	63	64	181	179
Tecartus | Europe
Disaggregation of Revenue [Line Items]
Total revenues	29	27	102	83
Tecartus | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	6	4	22	11
Yescarta
Disaggregation of Revenue [Line Items]
Total revenues	387	391	1,181	1,130
Yescarta | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	145	197	502	624
Yescarta | Europe
Disaggregation of Revenue [Line Items]
Total revenues	182	154	509	408
Yescarta | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	60	40	170	99
Trodelvy
Disaggregation of Revenue [Line Items]
Total revenues	332	283	960	764
Trodelvy | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	226	201	655	551
Trodelvy | Europe
Disaggregation of Revenue [Line Items]
Total revenues	80	62	217	169
Trodelvy | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	26	21	88	44
Total Other
Disaggregation of Revenue [Line Items]
Total revenues	201	216	705	658
Total Other | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	53	82	241	236
Total Other | Europe
Disaggregation of Revenue [Line Items]
Total revenues	80	72	236	224
Total Other | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	68	62	228	199
AmBisome
Disaggregation of Revenue [Line Items]
Total revenues	130	115	424	381
AmBisome | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	6	12	37	39
AmBisome | Europe
Disaggregation of Revenue [Line Items]
Total revenues	71	63	210	192
AmBisome | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	52	39	176	150
Other
Disaggregation of Revenue [Line Items]
Total revenues	71	101	281	277
Other | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	47	69	203	197
Other | Europe
Disaggregation of Revenue [Line Items]
Total revenues	8	9	26	31
Other | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	16	23	52	49
Royalty, contract and other revenues
Disaggregation of Revenue [Line Items]
Total revenues	30	56	111	138
Royalty, contract and other revenues | U.S.
Disaggregation of Revenue [Line Items]
Total revenues	17	32	66	57
Royalty, contract and other revenues | Europe
Disaggregation of Revenue [Line Items]
Total revenues	13	23	43	77
Royalty, contract and other revenues | Rest of World
Disaggregation of Revenue [Line Items]
Total revenues	$ 1	$ 1	$ 2	$ 4

REVENUES - Summary of Revenues

REVENUES - Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue share with Janssen and royalties for licenses of intellectual property	$ 173	$ 166	$ 545	$ 517
Changes in estimates	$ 146	$ 111	$ 388	$ 347

REVENUES - Summary of Contract

REVENUES - Summary of Contract Balances (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract assets	$ 184	$ 117
Contract liabilities	$ 68	$ 109

FAIR VALUE MEASUREMENTS - Summa

FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Assets:
Available-for-sale debt securities		$ 2,426
Fair Value, Measurements, Recurring | Arcellx, Inc
Liabilities:
Equity securities subject to contractual sale restrictions	$ 561
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Total	5,517	8,639
Liabilities:
Total	615	570
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | MYR GmbH
Liabilities:
Liability for MYR GmbH (“MYR”) contingent consideration	222	228
Level 1 | Fair Value, Measurements, Recurring
Assets:
Total	5,510	6,633
Liabilities:
Total	343	283
Level 1 | Fair Value, Measurements, Recurring | MYR GmbH
Liabilities:
Liability for MYR GmbH (“MYR”) contingent consideration	0	0
Level 2 | Fair Value, Measurements, Recurring
Assets:
Total	7	2,007
Liabilities:
Total	49	59
Level 2 | Fair Value, Measurements, Recurring | MYR GmbH
Liabilities:
Liability for MYR GmbH (“MYR”) contingent consideration	0	0
Level 3 | Fair Value, Measurements, Recurring
Assets:
Total	0	0
Liabilities:
Total	222	228
Level 3 | Fair Value, Measurements, Recurring | MYR GmbH
Liabilities:
Liability for MYR GmbH (“MYR”) contingent consideration	222	228
U.S. treasury securities | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Available-for-sale debt securities	0	426
U.S. treasury securities | Level 1 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	426
U.S. treasury securities | Level 2 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
U.S. treasury securities | Level 3 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
U.S. government agencies securities | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Available-for-sale debt securities	0	127
U.S. government agencies securities | Level 1 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
U.S. government agencies securities | Level 2 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	127
U.S. government agencies securities | Level 3 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Non-U.S. government securities | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Available-for-sale debt securities	0	10
Non-U.S. government securities | Level 1 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Non-U.S. government securities | Level 2 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	10
Non-U.S. government securities | Level 3 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Certificates of deposit | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Available-for-sale debt securities	0	45
Certificates of deposit | Level 1 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Certificates of deposit | Level 2 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	45
Certificates of deposit | Level 3 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Corporate debt securities | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Available-for-sale debt securities	0	1,451
Corporate debt securities | Level 1 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Corporate debt securities | Level 2 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	1,451
Corporate debt securities | Level 3 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Residential mortgage and asset-backed securities | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Available-for-sale debt securities	0	367
Residential mortgage and asset-backed securities | Level 1 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Residential mortgage and asset-backed securities | Level 2 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	367
Residential mortgage and asset-backed securities | Level 3 | Fair Value, Measurements, Recurring
Assets:
Available-for-sale debt securities	0	0
Money market funds | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Equity securities	3,502	4,465
Money market funds | Level 1 | Fair Value, Measurements, Recurring
Assets:
Equity securities	3,502	4,465
Money market funds | Level 2 | Fair Value, Measurements, Recurring
Assets:
Equity securities	0	0
Money market funds | Level 3 | Fair Value, Measurements, Recurring
Assets:
Equity securities	0	0
Publicly traded equity securities | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Equity securities	1,665	1,458
Publicly traded equity securities | Level 1 | Fair Value, Measurements, Recurring
Assets:
Equity securities	1,665	1,458
Publicly traded equity securities | Level 2 | Fair Value, Measurements, Recurring
Assets:
Equity securities	0	0
Publicly traded equity securities | Level 3 | Fair Value, Measurements, Recurring
Assets:
Equity securities	0	0
Deferred compensation plan | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Equity securities	343	284
Liabilities:
Deferred compensation plan	343	283
Deferred compensation plan | Level 1 | Fair Value, Measurements, Recurring
Assets:
Equity securities	343	284
Liabilities:
Deferred compensation plan	343	283
Deferred compensation plan | Level 2 | Fair Value, Measurements, Recurring
Assets:
Equity securities	0	0
Liabilities:
Deferred compensation plan	0	0
Deferred compensation plan | Level 3 | Fair Value, Measurements, Recurring
Assets:
Equity securities	0	0
Liabilities:
Deferred compensation plan	0	0
Foreign currency derivative contracts | Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement
Assets:
Foreign currency derivative contracts	7	7
Liabilities:
Foreign currency derivative contracts	49	59
Foreign currency derivative contracts | Level 1 | Fair Value, Measurements, Recurring
Assets:
Foreign currency derivative contracts	0	0
Liabilities:
Foreign currency derivative contracts	0	0
Foreign currency derivative contracts | Level 2 | Fair Value, Measurements, Recurring
Assets:
Foreign currency derivative contracts	7	7
Liabilities:
Foreign currency derivative contracts	49	59
Foreign currency derivative contracts | Level 3 | Fair Value, Measurements, Recurring
Assets:
Foreign currency derivative contracts	0	0
Liabilities:
Foreign currency derivative contracts	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Addit

FAIR VALUE MEASUREMENTS - Additional Information (Details) € in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2021 EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
In-process research and development impairment	$ 1,750	$ 0	$ 4,180	$ 0
Immunomedics | Fair Value, Nonrecurring | Level 3 | Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Future royalties	1,000		1,000		$ 1,200
Immunomedics | Fair Value, Nonrecurring | Level 3 | Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Future royalties	$ 1,200		$ 1,200		$ 1,200
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contract maturities (in months)	18 months		18 months
Maximum | MYR GmbH
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability for MYR GmbH (“MYR”) contingent consideration | €						€ 300

FAIR VALUE MEASUREMENTS - Sum_2

FAIR VALUE MEASUREMENTS - Summary of Total Estimated Fair Value and Carrying Value of Senior Unsecured Notes (Details) - Level 2 - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities
Fair value	$ 20,931	$ 22,567
Carrying Value
Fair Value, Assets and Liabilities
Carrying value	$ 22,094	$ 23,834

FAIR VALUE MEASUREMENTS - Sum_3

FAIR VALUE MEASUREMENTS - Summary of Change in Fair Value of Contingent Consideration Liability (Details) - MYR GmbH - Contingent Consideration - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 208	$ 288	$ 228	$ 275
Changes in valuation assumptions	5	(2)	(6)	3
Effect of foreign exchange remeasurement	9	(11)	1	(4)
Ending balance	$ 222	$ 275	$ 222	$ 275

AVAILABLE-FOR-SALE DEBT SECUR_3

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities (Details) $ in Millions	Dec. 31, 2023 USD ($)
Available-for-Sale Debt Securities
Amortized Cost	$ 2,430
Gross Unrealized Gains	5
Gross Unrealized Losses	(10)
Estimated Fair Value	2,426
U.S. treasury securities
Available-for-Sale Debt Securities
Amortized Cost	427
Gross Unrealized Gains	0
Gross Unrealized Losses	(1)
Estimated Fair Value	426
U.S. government agencies securities
Available-for-Sale Debt Securities
Amortized Cost	127
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Value	127
Non-U.S. government securities
Available-for-Sale Debt Securities
Amortized Cost	10
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Value	10
Certificates of deposit
Available-for-Sale Debt Securities
Amortized Cost	45
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Value	45
Corporate debt securities
Available-for-Sale Debt Securities
Amortized Cost	1,455
Gross Unrealized Gains	4
Gross Unrealized Losses	(8)
Estimated Fair Value	1,451
Residential mortgage and asset-backed securities
Available-for-Sale Debt Securities
Amortized Cost	366
Gross Unrealized Gains	1
Gross Unrealized Losses	0
Estimated Fair Value	$ 367

AVAILABLE-FOR-SALE DEBT SECUR_4

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities Been in Continuous Unrealized Loss Position (Details) $ in Millions	Dec. 31, 2023 USD ($)
Gross Unrealized Losses
Less than 12 months	$ (2)
12 months or longer	(8)
Total	(10)
Estimated Fair Value
Less than 12 months	727
12 months or longer	624
Total	1,351
U.S. treasury securities
Gross Unrealized Losses
Less than 12 months	0
12 months or longer	(1)
Total	(1)
Estimated Fair Value
Less than 12 months	161
12 months or longer	48
Total	209
U.S. government agencies securities
Gross Unrealized Losses
Less than 12 months	0
12 months or longer	0
Total	0
Estimated Fair Value
Less than 12 months	106
12 months or longer	2
Total	108
Non-U.S. government securities
Gross Unrealized Losses
Less than 12 months	0
12 months or longer	0
Total	0
Estimated Fair Value
Less than 12 months	5
12 months or longer	5
Total	10
Corporate debt securities
Gross Unrealized Losses
Less than 12 months	(1)
12 months or longer	(7)
Total	(8)
Estimated Fair Value
Less than 12 months	333
12 months or longer	546
Total	878
Residential mortgage and asset-backed securities
Gross Unrealized Losses
Less than 12 months	0
12 months or longer	0
Total	0
Estimated Fair Value
Less than 12 months	123
12 months or longer	24
Total	$ 147

AVAILABLE-FOR-SALE DEBT SECUR_5

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Available-for-Sale Debt Securities (Details) $ in Millions	Dec. 31, 2023 USD ($)
Available-for-Sale Debt Securities
Total	$ 2,426
Cash and cash equivalents
Available-for-Sale Debt Securities
Total	83
Short-term marketable debt securities
Available-for-Sale Debt Securities
Total	1,179
Long-term marketable debt securities
Available-for-Sale Debt Securities
Total	$ 1,163

AVAILABLE-FOR-SALE DEBT SECUR_6

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Equity method investments and other equity investments without readily determinable fair values:
Other long-term assets	$ 382	$ 340
Equity Securities, FV-NI And Without Readily Determinable Fair Value And Equipment Method Investments [Abstract]
Total	5,892	6,547
Cash and cash equivalents
Equity securities measured at fair value:
Equity securities measured at fair value	3,502	4,465
Prepaid and other current assets
Equity securities measured at fair value:
Equity securities measured at fair value	1,660	1,086
Other long-term assets
Equity securities measured at fair value:
Equity securities measured at fair value	$ 348	$ 656

AVAILABLE-FOR-SALE DEBT SECUR_7

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Galapagos
Available-for-Sale Debt Securities
Marketable equity securities	$ 483
Equity securities subject to contractual sale restrictions		$ 686
Arcus
Available-for-Sale Debt Securities
Marketable equity securities	$ 460	$ 283

AVAILABLE-FOR-SALE DEBT SECUR_8

AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Net Unrealized Gains and Losses on Equity Securities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Securities, Available-for-Sale [Abstract]
Unrealized (gain) loss, net	$ (257)	$ 128	$ 155	$ 249

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Derivative [Line Items]
Outstanding notional amount	$ 2,300		$ 2,300		$ 2,500
Discontinuances of cash flow hedges	$ 0	$ 0	$ 0	$ 0
Maximum
Derivative [Line Items]
Maturities of derivative instruments (in months)	18 months		18 months
Time estimate for gains (losses) to be reclassified from AOCI to product sales (in months)			12 months

DERIVATIVE FINANCIAL INSTRUME_4

DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Total Derivative Assets	$ 7	$ 7
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Derivative financial instruments	(7)	(7)
Cash collateral received / pledged	0	0
Net amount (legal offset)	0	0
Total Derivative Liabilities	49	59
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Derivative financial instruments	(7)	(7)
Cash collateral received / pledged	0	0
Net amount (legal offset)	42	52
Foreign currency exchange contracts designated as hedges
Derivatives, Fair Value [Line Items]
Total Derivative Assets	4	6
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Total Derivative Liabilities	40	45
Foreign currency exchange contracts not designated as hedges
Derivatives, Fair Value [Line Items]
Total Derivative Assets	3	1
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Total Derivative Liabilities	9	15
Prepaid and other current assets | Foreign currency exchange contracts designated as hedges
Derivatives, Fair Value [Line Items]
Total Derivative Assets	4	6
Prepaid and other current assets | Foreign currency exchange contracts not designated as hedges
Derivatives, Fair Value [Line Items]
Total Derivative Assets	3	1
Other long-term assets | Foreign currency exchange contracts designated as hedges
Derivatives, Fair Value [Line Items]
Total Derivative Assets	0	0
Other long-term assets | Foreign currency exchange contracts not designated as hedges
Derivatives, Fair Value [Line Items]
Total Derivative Assets	0	0
Other current liabilities | Foreign currency exchange contracts designated as hedges
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Total Derivative Liabilities	34	38
Other current liabilities | Foreign currency exchange contracts not designated as hedges
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Total Derivative Liabilities	9	15
Other long-term obligations | Foreign currency exchange contracts designated as hedges
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Total Derivative Liabilities	6	7
Other long-term obligations | Foreign currency exchange contracts not designated as hedges
Gross amounts not offset on the Condensed Consolidated Balance Sheets:
Total Derivative Liabilities	$ 0	$ 0

DERIVATIVE FINANCIAL INSTRUME_5

DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Derivative Contracts (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Net (loss) gain recognized in Accumulated other comprehensive income	$ (70)	$ 75	$ 23	$ 74
Net gain reclassified from Accumulated other comprehensive income into Product sales	14	16	19	50
Net (loss) gain recognized in Other (income) expense, net	$ (2)	$ (4)	$ 51	$ 46

ACQUISITIONS, COLLABORATIONS _2

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) shares in Millions, $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Feb. 22, 2023 USD ($)

Aug. 31, 2024 USD ($)

Jul. 31, 2024 USD ($)

Mar. 31, 2024 USD ($)

Jan. 31, 2024 USD ($) designee shares

Oct. 31, 2023 USD ($)

May 31, 2023 USD ($)

Sep. 30, 2024 USD ($)

Jun. 30, 2024 USD ($)

Mar. 31, 2024 USD ($)

Dec. 31, 2023 USD ($)

Sep. 30, 2023 USD ($)

Jun. 30, 2023 USD ($)

Mar. 31, 2023 USD ($)

Sep. 30, 2024 USD ($)

Sep. 30, 2023 USD ($)

Dec. 31, 2023 USD ($)

Jan. 30, 2023

Business Combination, Separately Recognized Transactions [Line Items]

Acquired in-process research and development expenses

$ 505

$ 91

$ 4,674

$ 808

Arcus

Business Combination, Separately Recognized Transactions [Line Items]

Ownership interest, shares (in shares) | shares

30.1

Ownership (as a percent)

33%

Arcellx, Inc | Global Strategic Collaboration Agreement

Business Combination, Separately Recognized Transactions [Line Items]

Acquired in-process research and development expenses

68

$ 101

$ 212

Maximum potential future milestone payments

$ 1,500

$ 1,500

Payments to acquire equity securities

299

Revenue, performance obligation, percentage of U.S. profits

50%

Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc

Business Combination, Separately Recognized Transactions [Line Items]

Revenue, performance obligation, percentage of U.S. profits

50%

Arcus

Business Combination, Separately Recognized Transactions [Line Items]

Additional interest acquired, shares (in shares) | shares

15.2

Additional equity investment

$ 320

Option fee

$ 100

Number of designees | designee

3

Arcus | Prepaid and other current assets

Business Combination, Separately Recognized Transactions [Line Items]

Additional equity investment

$ 233

Other (Income) Expense | Arcus

Business Combination, Separately Recognized Transactions [Line Items]

Additional equity investment

$ 87

CymaBay

Business Combination, Separately Recognized Transactions [Line Items]

Total consideration transferred

$ 3,900

Acquired in-process research and development expenses

$ 3,900

$ 3,900

Share-based compensation expense

133

Asset acquisition, assets acquired

263

263

Asset acquisition, liabilities assumed

$ 228

228

Change of control payment

$ 101

Settlement of remaining liability

$ 108

CymaBay | Janssen Pharmaceutica NV

Business Combination, Separately Recognized Transactions [Line Items]

Payment to extinguish a future royalty obligation

$ 320

CymaBay | Research and development expenses

Business Combination, Separately Recognized Transactions [Line Items]

Share-based compensation expense

67

CymaBay | Selling, general and administrative expenses

Business Combination, Separately Recognized Transactions [Line Items]

Share-based compensation expense

$ 67

XinThera, Inc

Business Combination, Separately Recognized Transactions [Line Items]

Acquired in-process research and development expenses

$ 50

$ 170

Cash consideration

$ 200

Maximum potential future milestone payments

$ 760

Tmunity Therapeutics

Business Combination, Separately Recognized Transactions [Line Items]

Acquired in-process research and development expenses

244

Cash consideration

$ 300

Tmunity Therapeutics | Tmunity And University Of Pennsylvania

Business Combination, Separately Recognized Transactions [Line Items]

Acquired in-process research and development expenses

$ 47

$ 25

Maximum potential future milestone payments

$ 1,000

INTANGIBLE ASSETS - Summary of

INTANGIBLE ASSETS - Summary of Intangible Assets, Net (Details) - USD ($) $ in Millions	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross  Carrying Amount	$ 31,879		$ 31,819
Accumulated Amortization	(14,224)		(12,436)
Foreign Currency Translation Adjustment	1		1
Net Carrying Amount	17,656		19,384
Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]
Gross  Carrying Amount	2,890		7,070
Foreign Currency Translation Adjustment	0		0
Net Carrying Amount	2,890		7,070
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Gross  Carrying Amount	34,769		38,889
Accumulated Amortization	(14,224)		(12,436)
Foreign Currency Translation Adjustment	1		1
Net Carrying Amount	20,546		26,454
In Process Research And Development NSCLC
Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]
Gross  Carrying Amount	1,800		5,900
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Indefinite-lived intangible assets, fair value	1,800	$ 3,500
In Process Research And Development Bulevirtide
Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]
Gross  Carrying Amount	1,100		1,100
Intangible asset – sofosbuvir
Finite-Lived Intangible Assets [Line Items]
Gross  Carrying Amount	10,720		10,720
Accumulated Amortization	(7,574)		(7,050)
Foreign Currency Translation Adjustment	0		0
Net Carrying Amount	3,146		3,670
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	(7,574)		(7,050)
Intangible asset – axicabtagene ciloleucel
Finite-Lived Intangible Assets [Line Items]
Gross  Carrying Amount	7,110		7,110
Accumulated Amortization	(2,619)		(2,314)
Foreign Currency Translation Adjustment	0		0
Net Carrying Amount	4,491		4,796
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	(2,619)		(2,314)
Intangible asset – Trodelvy
Finite-Lived Intangible Assets [Line Items]
Gross  Carrying Amount	11,730		11,730
Accumulated Amortization	(2,813)		(2,002)
Foreign Currency Translation Adjustment	0		0
Net Carrying Amount	8,917		9,728
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	(2,813)		(2,002)
Intangible asset – Hepcludex
Finite-Lived Intangible Assets [Line Items]
Gross  Carrying Amount	845		845
Accumulated Amortization	(308)		(243)
Foreign Currency Translation Adjustment	0		0
Net Carrying Amount	537		602
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	(308)		(243)
Other
Finite-Lived Intangible Assets [Line Items]
Gross  Carrying Amount	1,474		1,414
Accumulated Amortization	(911)		(827)
Foreign Currency Translation Adjustment	1		1
Net Carrying Amount	565		588
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Accumulated Amortization	$ (911)		$ (827)

INTANGIBLE ASSETS - Additional

INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Intangible Assets [Line Items]
In-process research and development impairment	$ 1,750		$ 0	$ 4,180	$ 0
In Process Research And Development NSCLC
Intangible Assets [Line Items]
In-process research and development impairment	1,800	$ 2,400		4,200
Indefinite-lived intangible assets, fair value	$ 1,800	$ 3,500		$ 1,800
In Process Research And Development NSCLC | Immunomedics | Discount Rate
Intangible Assets [Line Items]
Discount rate, measurement input (as a percent)	7%	7%		7%

OTHER FINANCIAL INFORMATION - S

OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Other Financial Information [Abstract]
Accounts receivable	$ 5,462	$ 5,495
Less: allowances for chargebacks	722	679
Less: allowances for cash discounts and other	89	101
Less: allowances for credit losses	65	56
Accounts receivable, net	$ 4,587	$ 4,660

OTHER FINANCIAL INFORMATION -_2

OTHER FINANCIAL INFORMATION - Summary of Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Other Financial Information [Abstract]
Raw materials	$ 1,332	$ 1,246
Work in process	684	847
Finished goods	1,419	1,272
Total	3,435	3,366
Inventories	1,869	1,787
Other long-term assets	$ 1,566	$ 1,578

OTHER FINANCIAL INFORMATION -_3

OTHER FINANCIAL INFORMATION - Summary of Components of Other Current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Other Financial Information [Abstract]
Compensation and employee benefits	$ 1,051	$ 1,201
Income taxes payable	1,536	1,208
Allowance for sales returns	321	387
Other	1,988	2,334
Other current liabilities	$ 4,896	$ 5,130

OTHER FINANCIAL INFORMATION -_4

OTHER FINANCIAL INFORMATION - Summary of Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 18,197	$ 21,094	$ 22,749	$ 21,209
Net unrealized (loss) gain			58	72
Reclassifications to net income			(12)	(42)
Other comprehensive (loss) income, net	(20)	21	45	30
Ending balance	18,390	22,242	18,390	22,242
Accumulated Other Comprehensive Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	93	10	28	2
Other comprehensive (loss) income, net	(20)	21	45	30
Ending balance	73	31	73	31
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			62	2
Net unrealized (loss) gain			38	(3)
Reclassifications to net income			0	0
Other comprehensive (loss) income, net			38	(3)
Ending balance	100	(1)	100	(1)
Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(5)	(33)
Net unrealized (loss) gain			0	10
Reclassifications to net income			5	2
Other comprehensive (loss) income, net			5	11
Ending balance	0	(22)	0	(22)
Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			(29)	33
Net unrealized (loss) gain			20	65
Reclassifications to net income			(17)	(44)
Other comprehensive (loss) income, net			3	21
Ending balance	$ (27)	$ 54	$ (27)	$ 54

OTHER FINANCIAL INFORMATION - A

OTHER FINANCIAL INFORMATION - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 28	$ 112
Research and development expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges	5	68
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 23	$ 45

DEBT AND CREDIT FACILITIES - Su

DEBT AND CREDIT FACILITIES - Summary of Carrying Amount of Borrowings Under Various Financing Arrangements (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total debt, net	$ 23,249	$ 24,987
Less: Current portion of long-term debt, net	1,812	1,798
Total Long-term debt, net	21,437	23,189
Senior Notes and Medium-Term Notes
Debt Instrument [Line Items]
Total senior unsecured notes	22,094	23,834
Liability related to future royalties
Debt Instrument [Line Items]
Total debt, net	$ 1,155	1,153
3.70% Senior Unsecured Notes Due April 2024 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	3.70%
Total debt, net	$ 0	1,750
3.50% Senior Unsecured Notes Due February 2025 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	3.50%
Total debt, net	$ 1,750	1,749
3.65% Senior Unsecured Notes Due March 2026 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	3.65%
Total debt, net	$ 2,746	2,744
2.95% Senior Unsecured Notes Due March 2027 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	2.95%
Total debt, net	$ 1,248	1,248
1.20% Senior Unsecured Notes Due October 2027 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	1.20%
Total debt, net	$ 748	747
1.65% Senior Unsecured Notes Due October 2030 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	1.65%
Total debt, net	$ 995	994
5.25% Senior Unsecured Notes Due October 2033 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	5.25%
Total debt, net	$ 993	992
4.60% Senior Unsecured Notes Due September 2035 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	4.60%
Total debt, net	$ 994	993
4.00% Senior Unsecured Notes Due September 2036 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	4%
Total debt, net	$ 743	743
2.60% Senior Unsecured Notes Due October 2040 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	2.60%
Total debt, net	$ 989	988
5.65% Senior Unsecured Notes Due December 2041 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	5.65%
Total debt, net	$ 996	996
4.80% Senior Unsecured Notes Due April 2044 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	4.80%
Total debt, net	$ 1,737	1,737
4.50% Senior Unsecured Notes Due February 2045 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	4.50%
Total debt, net	$ 1,735	1,734
4.75% Senior Unsecured Notes Due March 2046 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	4.75%
Total debt, net	$ 2,223	2,222
4.15% Senior Unsecured Notes Due March 2047 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	4.15%
Total debt, net	$ 1,730	1,729
2.80% Senior Unsecured Notes Due October 2050 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	2.80%
Total debt, net	$ 1,479	1,478
5.55% Senior Unsecured Notes Due October 2053 | Senior Notes
Debt Instrument [Line Items]
Interest Rate	5.55%
Total debt, net	$ 988	$ 988

DEBT AND CREDIT FACILITIES - Ad

DEBT AND CREDIT FACILITIES - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	Apr. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Repayments of debt		$ 1,963	$ 2,250
Senior Notes
Debt Instrument [Line Items]
Repayments of debt	$ 1,750
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Amounts outstanding under revolving credit facilities		$ 0			$ 0
Line of Credit | Revolving Credit Facility | Credit Facility Due June 2025
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 2,500	$ 2,500
Line of Credit | Revolving Credit Facility | Credit Facility Due June 2029
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 2,500

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	1 Months Ended				6 Months Ended	9 Months Ended
	Jul. 31, 2024 claim	Nov. 30, 2023 patent	May 31, 2023 USD ($)	Mar. 31, 2022 patent	Dec. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) plaintiff lawsuit	Apr. 30, 2020 agreement
Loss Contingencies [Line Items]
Number of patents challenged | patent		2		4
Number of patents | patent				6
Settlement payment					$ 525
Number of claims dismissed | claim	2
Settlement amount awarded			$ 525
Pre-Exposure Prophylaxis
Loss Contingencies [Line Items]
Number of material transfer agreements | agreement							3
Product Liability
Loss Contingencies [Line Items]
Number of class action lawsuits | lawsuit						1
Number of plaintiffs involved | plaintiff						25,000
Product Liability - California
Loss Contingencies [Line Items]
Settlement amount awarded						$ 40
Number of plaintiffs involved | plaintiff						2,625
Percentage of eligible plaintiffs participating in settlement						98%

EARNINGS (LOSS) PER SHARE - Sum

EARNINGS (LOSS) PER SHARE - Summary of the Calculation of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net income (loss) attributable to Gilead	$ 1,253	$ 2,180	$ (1,303)	$ 4,236
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares)	1,247	1,248	1,247	1,249
Dilutive effect of stock options and equivalents (in shares)	7	8	0	10
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares)	1,254	1,257	1,247	1,259
Basic earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1	$ 1.75	$ (1.04)	$ 3.39
Diluted earnings (loss) per share attributable to Gilead (in dollars per share)	$ 1	$ 1.73	$ (1.04)	$ 3.37

EARNINGS (LOSS) PER SHARE - Add

EARNINGS (LOSS) PER SHARE - Additional Information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Antidilutive securities excluded from diluted earnings (loss) per share computation (in shares)	7	6	14	4

INCOME TAXES - Summary of Incom

INCOME TAXES - Summary of Income Tax (Benefit) Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ 956	$ 2,318	$ (1,477)	$ 5,206
Income tax (benefit) expense	$ (297)	$ 146	$ (174)	$ 1,010
Effective tax rate	(31.10%)	6.30%	11.80%	19.40%

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Contingency [Line Items]
Effective income tax rate reconciliation (as a percent)	(31.10%)		6.30%	11.80%	19.40%
In-process research and development impairment	$ 1,750		$ 0	$ 4,180	$ 0
Acquired in-process research and development expenses	505		$ 91	4,674	$ 808
Increase in unrecognized tax benefits				200
Unrecognized tax benefits, increase due to current year unrecognized tax benefits				700
Unrecognized tax benefits, reductions to prior year tax positions and settlements				500
In Process Research And Development NSCLC
Income Tax Contingency [Line Items]
In-process research and development impairment	$ 1,800	$ 2,400		4,200
CymaBay
Income Tax Contingency [Line Items]
Acquired in-process research and development expenses		$ 3,900		$ 3,900